|Table of Contents|

The effects of topotecan on neuroblastoma cell line SH-SY5Y proliferation,invasion and migration

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 04
Page:
521-524
Research Field:
Publishing date:

Info

Title:
The effects of topotecan on neuroblastoma cell line SH-SY5Y proliferation,invasion and migration
Author(s):
Wang Guowen; Chen Fei; Xu Dehui; Ma Feihu; Zhao Hongyu
Department of Neurosurgery,Shengjing Hospital of China Medical University,Liaoning Shenyang 110004，China.
Keywords:
neuroblastoma; topotecan; invasion/metastasis; matrix metalloproteinase 9; matrix metalloproteinase 2
PACS:
R739.4
DOI:
10.3969/j.issn.1672-4992.2017.04.004
Abstract:
Objective:To investigate the main reason of the refractory in neuroblastoma(NB),and the chief mechanism whether topotecan could influence the proliferation,apoptosis,invasion and migration of NB cell line SH-SY5Y has been investigated in this paper.Methods:SH-SY5Y cells were treated with topotecan in the different concentrations.The cell growth was evaluated by cell counting kit-8 (CCK-8) assay.Cell invasion and migration were analyzed by wound healing assay/Tranwell double chamber assay.Expression of matrix metalloproteinase 9（MMP9）,matrix metalloproteinase 2（MMP2）in cells was detected by Western-Blotting assay.Results:We demonstrated that topotecan inhibited SH-SY5Y proliferation in time-and dose-dependence.Topotecan inhibited cell migration and invasion and reduced the expression of MMP9 and MMP2 in a dose-dependent manner.Conclusion:Topotecan inhibited the proliferation of NB cell and restrained its invasion and migration by down-regulation of MMP9 and MMP2.

References:

［1］Brodeur GM,Azar C,Brother M,et al.Neuroblastoma.Effect of genetic factors on prognosis and treatment［J］.Cancer,1992,70(6 Suppl):1685-1694.
[2]Armstrong JL,Martin S,Illingworth NA,et al.The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide［J］.Oncol Rep,2012,27(1):293-298.
[3]Fabio M,Maria VC,Vito P.Evaluation of bone marrow as a metastatic site of human neuroblastoma［J］.Ann N Y Acad Sci,2015,1335:23-31.
[4]Dubois SG,Kalika Y,Lukens JN,et al.Metastatic sitesin stage IV and IVS neuroblastoma correlate with age,tumor biology,and survival［J］.Pediatr Hematol Oncol,1999,21:181-189.
[5]Simon T,Langle A,Harnischmacher U,et al.Topotecan,cyclophosphamide,and etoposide (TCE) in the treatment of high-risk neuroblastoma.Results of a phase-Ⅱ trial［J］.Cancer Res Clin Oncol,2007,133(9):653-661.
[6]Ara T，DeClerck YA.Mechanisms of invasion and metastasis in human neuroblastoma［J］.Cancer Metastasis Rev,2006,25(4):645-657.
[7]Aimes RT，Quigley JP.Matrix metalloproteinase-2 is an interstitial collagenase:Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4- length fragments［J］.J Biol Chem,1995,270(11):5872-5876.
[8]Carol H,Houghton PJ,Morton CL,et al.Initial testing of topotecan by the pediatric preclinical testing program［J］.Pediatr Blood Cancer,2010,54(5):707-715.
[9]Nakashio A,Fujita N,Tsuruo T.Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway［J］.Int J Cancer,2002,98(2):36-41.
[10]Lin S,Sun L,Zhang Y.Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases［J］.Acta Pharmacol Sin,2009,30(5):628-636.
[11]Tonini GP,Nakagawara A,Berthold F,et al.Towards a turning point of neuroblastoma therapy［J］.Cancer Lett,2012,326(2):128-134.
[12]Brodeur GM.Neuroblastoma:Biological insights into a clinical enigma［J］.Nat Rev Cancer,2003,3(3):203-216.
[13]HaDuong JH,Blavier L,Baniwal SK,et al.Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis［J］.Int J Cancer,2015,137(4):797-809.
[14]Kollmannsberger C,Mross K,Jakob A,et al.Topotecan-a novel topoisomerase I inhibitor:Pharmacology and clinical experience［J］.Oncology,1999,56(1):1-12.
[15]Kim MK,James J,Annunziata CM.Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells［J］.BMC Cancer,2015,15:196.
[16]Oberhoff C,Kieback DG,Würstlein R,et al.Topotecan chemotherapy in patients with breast cancer and brain metastases:Results of a pilot study［J］.Onkologie,2001,24(3):256-260.
[17]Megison ML,Gillory LA,Beierle EA,et al.Cell survival signaling in neuroblastoma［J］.Anticancer Agents Med Chem,2013,13(4):563-575.
[18]Dünne AA,Grbe A,Sesterhenn AM,et al.Influence of matrix metallo proteinase 9 (MMP-9)on the metastatic behavior of oropharyngeal cancer［J］.Anticancer Res,2005,25(6B):4129-4134.

Memo

Memo:
国家自然科学基金资助项目(编号：81172410)
Last Update: 2016-12-29